Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis
Objective To investigate the relation between TMB and the efficiency of PD-1/PD-L1 inhibitors treatment for non-small-cell lung cancer. Methods Studies were searched from PubMed, Embase, Cochrane Library database, Chinese Biomedical Literature Database and Wanfang Database up to March 25, 2020. RevM...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2021-03-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0765.htm |
| _version_ | 1818848750421934080 |
|---|---|
| author | SHEN Shijun WANG Qiaoli YANG Jinjiang LI Guojian LI Mengli ZHANG Xiaoli GAN Ping |
| author_facet | SHEN Shijun WANG Qiaoli YANG Jinjiang LI Guojian LI Mengli ZHANG Xiaoli GAN Ping |
| author_sort | SHEN Shijun |
| collection | DOAJ |
| description | Objective To investigate the relation between TMB and the efficiency of PD-1/PD-L1 inhibitors treatment for non-small-cell lung cancer. Methods Studies were searched from PubMed, Embase, Cochrane Library database, Chinese Biomedical Literature Database and Wanfang Database up to March 25, 2020. RevMan 5.3 software and STATA15.0 were used for analysis. Results Twelve literatures were involved, including 1209 patients. TMB significantly improved PFS (HR=0.54, 95%CI: 0.42-0.70, P < 0.001) but reduced the ORR (OR=4.41, 95%CI: 2.54-7.63, P < 0.001) of NSCLC patients treated with PD-1/PD-L1 inhibitors. The subgroup analyses showed that the predictive value of TMB was significant in non-small cell lung cancer treated by PD-1/PD-L1 inhibitors combined with anti-CTLA-4 therapy or chemotherapy. No significant publication bias was observed by the Begg's test and Egger's test. Conclusion High tumor mutation burden may predict the improved PFS of non-small cell lung cancer by PD-1/PD-L1 inhibitors treatment, but its predictive value for OS, ORR and long-term survival need more exploration. |
| first_indexed | 2024-12-19T06:22:18Z |
| format | Article |
| id | doaj.art-69c9dc3696fc40828273a351904e3742 |
| institution | Directory Open Access Journal |
| issn | 1000-8578 1000-8578 |
| language | zho |
| last_indexed | 2024-12-19T06:22:18Z |
| publishDate | 2021-03-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-69c9dc3696fc40828273a351904e37422022-12-21T20:32:40ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85781000-85782021-03-0148328128710.3971/j.issn.1000-8578.2021.20.07658578.2021.20.0765Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysisSHEN Shijun0WANG Qiaoli1YANG Jinjiang2LI Guojian3LI Mengli4ZHANG Xiaoli5GAN Ping6Department of Stomach and Small Intestine Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, ChinaGraduate School of Kunming Medical University, Kunming 650500, ChinaDepartment of Vascular Surgery, The Fourth Affiliated Hospital of Kunming Medical University, Kunming 650021, ChinaDepartment of Vascular Surgery, The Fourth Affiliated Hospital of Kunming Medical University, Kunming 650021, ChinaGraduate School of Kunming Medical University, Kunming 650500, ChinaGraduate School of Kunming Medical University, Kunming 650500, ChinaDepartment of Stomach and Small Intestine Surgery, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, ChinaObjective To investigate the relation between TMB and the efficiency of PD-1/PD-L1 inhibitors treatment for non-small-cell lung cancer. Methods Studies were searched from PubMed, Embase, Cochrane Library database, Chinese Biomedical Literature Database and Wanfang Database up to March 25, 2020. RevMan 5.3 software and STATA15.0 were used for analysis. Results Twelve literatures were involved, including 1209 patients. TMB significantly improved PFS (HR=0.54, 95%CI: 0.42-0.70, P < 0.001) but reduced the ORR (OR=4.41, 95%CI: 2.54-7.63, P < 0.001) of NSCLC patients treated with PD-1/PD-L1 inhibitors. The subgroup analyses showed that the predictive value of TMB was significant in non-small cell lung cancer treated by PD-1/PD-L1 inhibitors combined with anti-CTLA-4 therapy or chemotherapy. No significant publication bias was observed by the Begg's test and Egger's test. Conclusion High tumor mutation burden may predict the improved PFS of non-small cell lung cancer by PD-1/PD-L1 inhibitors treatment, but its predictive value for OS, ORR and long-term survival need more exploration.http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0765.htmmmunotherapymeta-analysisnon-small cell lung cancerpd-1/pd-l1 inhibitorstumor mutation burden |
| spellingShingle | SHEN Shijun WANG Qiaoli YANG Jinjiang LI Guojian LI Mengli ZHANG Xiaoli GAN Ping Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis Zhongliu Fangzhi Yanjiu mmunotherapy meta-analysis non-small cell lung cancer pd-1/pd-l1 inhibitors tumor mutation burden |
| title | Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis |
| title_full | Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis |
| title_fullStr | Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis |
| title_full_unstemmed | Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis |
| title_short | Predictive Value of Tumor Mutation Burden for PD-1/PD-L1 Inhibitors Treatment on Non-small Cell Lung Cancer: A Meta-analysis |
| title_sort | predictive value of tumor mutation burden for pd 1 pd l1 inhibitors treatment on non small cell lung cancer a meta analysis |
| topic | mmunotherapy meta-analysis non-small cell lung cancer pd-1/pd-l1 inhibitors tumor mutation burden |
| url | http://html.rhhz.net/ZLFZYJ/html/8578.2021.20.0765.htm |
| work_keys_str_mv | AT shenshijun predictivevalueoftumormutationburdenforpd1pdl1inhibitorstreatmentonnonsmallcelllungcancerametaanalysis AT wangqiaoli predictivevalueoftumormutationburdenforpd1pdl1inhibitorstreatmentonnonsmallcelllungcancerametaanalysis AT yangjinjiang predictivevalueoftumormutationburdenforpd1pdl1inhibitorstreatmentonnonsmallcelllungcancerametaanalysis AT liguojian predictivevalueoftumormutationburdenforpd1pdl1inhibitorstreatmentonnonsmallcelllungcancerametaanalysis AT limengli predictivevalueoftumormutationburdenforpd1pdl1inhibitorstreatmentonnonsmallcelllungcancerametaanalysis AT zhangxiaoli predictivevalueoftumormutationburdenforpd1pdl1inhibitorstreatmentonnonsmallcelllungcancerametaanalysis AT ganping predictivevalueoftumormutationburdenforpd1pdl1inhibitorstreatmentonnonsmallcelllungcancerametaanalysis |